KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Income towards Parent Company: 2009-2024

Historic Income towards Parent Company for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Dec 2024 value amounting to $17.5 million.

  • Rigel Pharmaceuticals' Income towards Parent Company rose 124.62% to $27.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.2 million, marking a year-over-year increase of 2817.96%. This contributed to the annual value of $17.5 million for FY2024, which is 169.61% up from last year.
  • According to the latest figures from FY2024, Rigel Pharmaceuticals' Income towards Parent Company is $17.5 million, which was up 169.61% from -$25.1 million recorded in FY2023.
  • Rigel Pharmaceuticals' Income towards Parent Company's 5-year high stood at $17.5 million during FY2024, with a 5-year trough of -$58.6 million in FY2022.
  • For the 3-year period, Rigel Pharmaceuticals' Income towards Parent Company averaged around -$22.1 million, with its median value being -$25.1 million (2023).
  • As far as peak fluctuations go, Rigel Pharmaceuticals' Income towards Parent Company plummeted by 226.97% in 2022, and later soared by 169.61% in 2024.
  • Yearly analysis of 5 years shows Rigel Pharmaceuticals' Income towards Parent Company stood at -$29.7 million in 2020, then surged by 39.77% to -$17.9 million in 2021, then crashed by 226.97% to -$58.6 million in 2022, then soared by 57.16% to -$25.1 million in 2023, then skyrocketed by 169.61% to $17.5 million in 2024.